LAVIOLETTE PAUL A

SEC source: 0001437749-26-016208 · rdgdoc.xml · nonDerivative · entry 1

LAVIOLETTE PAUL A · CIK 0001191249 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,846

F1 · kind: The shares reported herein were acquired through the Company's at-the-market equity offering program established pursuant to that certain Equity Distribution Agreement, dated February 19, 2026, by and between the Company and TD Securities (USA) LLC, as sales agent. The shares were purchased during an open trading window under the Company's Insider Trading Policy and in accordance with applicable securities laws.

F2 · price: The shares reported herein were acquired in a negotiated through the Company's at-the-market equity offering program at the prevailing market bid price or better at the time of sale.

F3 · balance_after: Includes shares purchased through the Company's Employee Stock Purchase Plan in March 2026.

SEC source: 0001437749-26-016190 · rdgdoc.xml · nonDerivative · entry 1

LAVIOLETTE PAUL A · CIK 0001191249 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

F1 · kind: The shares reported herein were acquired through the Company's at-the-market equity offering program established pursuant to that certain Equity Distribution Agreement, dated February 19, 2026, by and between the Company and TD Securities (USA) LLC, as sales agent. The shares were purchased during an open trading window under the Company's Insider Trading Policy and in accordance with applicable securities laws.

F2 · price: The shares reported herein were acquired in a negotiated through the Company's at-the-market equity offering program at the prevailing market bid price or better at the time of sale.

SEC source: 0001225208-26-005052 · doc4.xml · nonDerivative · entry 1

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,552

F1 · shares: These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

SEC source: 0001225208-25-004953 · doc4.xml · nonDerivative · entry 1

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,301

F1 · shares: These restricted stock units were granted on May 9, 2025 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

SEC source: 0001437749-25-001016 · rdgdoc.xml · derivative · entry 2

LAVIOLETTE PAUL A · CIK 0001191249 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,050,000

Underlying: Common Stock · 1,050,000 shares

Expires 2035-01-09

F2 · derivative.exercise_date: The shares subject to this option are subject to five tranches of performance-based vesting criteria tied to certain operating targets and the Issuer's market capitalization ranging from $3 billion to $9 billion, in all cases, subject to the Reporting Person's continued service through each vesting milestone.

SEC source: 0001437749-25-001016 · rdgdoc.xml · derivative · entry 1

LAVIOLETTE PAUL A · CIK 0001191249 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 450,000

Underlying: Common Stock · 450,000 shares

Expires 2035-01-09

F1 · derivative.exercise_date: One-fourth of the shares subject to the option will vest on the three-year anniversary of the grant and the remaining shares will vest on the four-year anniversary of the grant, subject to the Reporting Person's continued service through each vesting date.

SEC source: 0001437749-24-026509 · rdgdoc.xml · derivative · entry 2

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2034-08-09

F2 · derivative.exercise_date: One-fourth of the shares subject to the option will vest on the date of the Issuer's next annual meeting of stockholders and the remaining shares will vest on a monthly basis over three years thereafter, subject to the Reporting Person's continued service through each vesting date.

SEC source: 0001437749-24-026509 · rdgdoc.xml · derivative · entry 1

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-08-09

F1 · derivative.exercise_date: One-third of the shares subject to the option will vest on the one-year anniversary of the grant and the remaining shares will vest on a monthly basis over two years thereafter, subject to the Reporting Person's continued service through each vesting date.

SEC source: 0001225208-24-005895 · doc4.xml · nonDerivative · entry 1

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,773

F1 · shares: These restricted stock units were granted on May 8, 2024 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

SEC source: 0001225208-23-005907 · doc4.xml · nonDerivative · entry 1

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,718

F1 · shares: These restricted stock units were granted on May 12, 2023 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

SEC source: 0001225208-22-006589 · doc4.xml · nonDerivative · entry 1

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,915

F1 · shares: These restricted stock units were granted on May 4, 2022 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

SEC source: 0001493152-21-030847 · ownership.xml · nonDerivative · entry 1

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By SV Health Investors, LLC

Disclosed balance after: 0

F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger dated as of July 29, 2021 (the "Merger Agreement") among the Issuer, Bioventus Inc. ("Bioventus"), Oyster Merger Sub I, Inc., a Delaware corporation, and a wholly owned subsidiary of Bioventus ("Merger Sub I"), Oyster Merger Sub II, LLC, a Delaware limited liability company, and a wholly owned subsidiary of Bioventus ("Merger Sub II"), under which (a) Merger Sub I merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Bioventus (the "First Merger") and (b) immediately following the consummation of the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving as Misonix, LLC (the "Second Merger" and together with the First Merger, the "Mergers").

F2 · shares: Pursuant to the Merger Agreement, at the effective time of the First Merger, each share of Issuer common stock was converted into the right to receive a per share amount (the "Merger Consideration") equal to either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and non-assessable shares of Class A common stock of Bioventus, $0.001 par value per share ("Bioventus Shares"). The disposition was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.

F3 · shares: Includes 50,000 options to purchase the Issuer's common stock which, pursuant to the Merger Agreement, at the effective time of the First Merger, automatically vested and thereafter were cancelled and converted into a right to purchase Bioventus Shares on the same terms and conditions that applied to the options immediately prior to the First Effective Time, adjusted by the Option Exchange Ratio (as defined in the Merger Agreement).

F1 · price: Disposed of pursuant to the Agreement and Plan of Merger dated as of July 29, 2021 (the "Merger Agreement") among the Issuer, Bioventus Inc. ("Bioventus"), Oyster Merger Sub I, Inc., a Delaware corporation, and a wholly owned subsidiary of Bioventus ("Merger Sub I"), Oyster Merger Sub II, LLC, a Delaware limited liability company, and a wholly owned subsidiary of Bioventus ("Merger Sub II"), under which (a) Merger Sub I merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Bioventus (the "First Merger") and (b) immediately following the consummation of the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving as Misonix, LLC (the "Second Merger" and together with the First Merger, the "Mergers").

F2 · price: Pursuant to the Merger Agreement, at the effective time of the First Merger, each share of Issuer common stock was converted into the right to receive a per share amount (the "Merger Consideration") equal to either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and non-assessable shares of Class A common stock of Bioventus, $0.001 par value per share ("Bioventus Shares"). The disposition was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.

F3 · price: Includes 50,000 options to purchase the Issuer's common stock which, pursuant to the Merger Agreement, at the effective time of the First Merger, automatically vested and thereafter were cancelled and converted into a right to purchase Bioventus Shares on the same terms and conditions that applied to the options immediately prior to the First Effective Time, adjusted by the Option Exchange Ratio (as defined in the Merger Agreement).

F4 · ownership.nature: The reporting person is a member of SV Health Investors, LLC ("SV Health Investors"). Under SV Health Investors Limited Liability Company Agreement, the reporting person is deemed to hold the reported option for the benefit of SV Health Investors, and must exercise the option solely upon the direction of SV Health Investors, which is entitled to the shares issued upon exercise. SV Health Investors may be deemed the indirect beneficial owner of the option, and the reporting person may be deemed the indirect beneficial owner of the option through his indirect interest in SV Health Investors. The reporting person disclaims beneficial ownership of the option except to the extent of his pecuniary interest therein.

SEC source: 0001209191-21-045181 · doc4.xml · nonDerivative · entry 1

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,846

F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the right to receive one share of the Registrant's common stock.

F2 · shares: Forfeiture restrictions will lapse on the RSUs on the first anniversary of the date of grant, provided that if the date of the 2022 annual meeting of stockholders is earlier, the restrictions will lapse on the date of the annual meeting.

F1 · price: Represents restricted stock units ("RSUs"). Each RSU represents the right to receive one share of the Registrant's common stock.

F3 · balance_after: The Reporting Person has assigned shares issued from prior grants of restricted stock units to SV Health Investors in accordance with its operating agreement and is expected to transfer the shares underlying this reported award upon vesting.

SEC source: 0001209191-21-045181 · doc4.xml · derivative · entry 2

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,025

Underlying: Common Stock · 10,025 shares

Expires 2028-06-30

F4 · security: Represents an equity award issued under the Registrant's Amended and Restated Incentive Compensation Plan in lieu of an annual cash retainer, paid quarterly in arrears for the quarter ended June 30, 2021.

F5 · derivative.exercise_date: The award is fully exercisable six months after the grant date, subject to earlier acceleration as approved by the Board of Directors.

SEC source: 0001493152-21-016050 · ownership.xml · derivative · entry 1

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By SV Health Investors, LLC

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-06-29

F1 · derivative.exercise_date: Award of Stock Options under the Misonix 2017 Equity Incentive Plan. Stock Options vest on June 30, 2022.

F2 · ownership.nature: The reporting person is a member of SV Health Investors, LLC ("SV Health Investors"). Under SV Health Investors Limited Liability Company Agreement, the reporting person is deemed to hold the reported option for the benefit of SV Health Investors, and must exercise the option solely upon the direction of SV Health Investors, which is entitled to the shares issued upon exercise. SV Health Investors may be deemed the indirect beneficial owner of the option, and the reporting person may be deemed the indirect beneficial owner of the option through his indirect interest in SV Health Investors. The reporting person disclaims beneficial ownership of the option except to the extent of his pecuniary interest therein.

SEC source: 0001225208-21-007761 · doc4.xml · nonDerivative · entry 1

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,615

F1 · shares: These restricted stock units were granted on May 5, 2021 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on the Issuer's Board.

SEC source: 0001209191-21-024782 · doc4.xml · derivative · entry 1

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,440

Underlying: Common Stock · 8,440 shares

Expires 2028-03-31

F1 · security: Represents an equity award issued under the Registrant's Amended and Restated Incentive Compensation Plan in lieu of an annual cash retainer, paid quarterly in arrears for the quarter ended March 31, 2021.

F2 · derivative.exercise_date: The award is fully exercisable six months after the grant date, subject to earlier acceleration as approved by the Board of Directors.

SEC source: 0001209191-21-001608 · doc4.xml · derivative · entry 1

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,323

Underlying: Common Stock · 34,323 shares

Expires 2028-12-31

F1 · security: Represents an equity award issued under the Registrant's Amended and Restated Incentive Compensation Plan in lieu of an annual cash retainer, paid quarterly in arrears for the quarter ended December 31, 2020.

F2 · derivative.exercise_date: The award is fully exercisable six months after the grant date, subject to earlier acceleration as approved by the Board of Directors.

SEC source: 0001209191-20-053280 · doc4.xml · derivative · entry 1

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,548

Underlying: Common Stock · 34,548 shares

Expires 2027-09-30

F1 · security: Represents an equity award issued under the Registrant's Amended and Restated Incentive Compensation Plan in lieu of an annual cash retainer, paid quarterly in arrears for the quarter ended September 30, 2020.

F2 · derivative.exercise_date: The award is fully exercisable six months after the grant date, subject to earlier acceleration as approved by the Board of Directors.

SEC source: 0001493152-20-012458 · ownership.xml · derivative · entry 1

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By SV Health Investors, LLC

Disclosed balance after: 3,060

Underlying: Common Stock · 3,060 shares

Expires 2030-06-29

F1 · derivative.exercise_date: Award of Stock Options under the Misonix 2017 Equity Incentive Plan. Stock Options vest on June 30, 2021.

F2 · ownership.nature: The reporting person is a member of SV Health Investors, LLC ("SV Health Investors"). Under SV Health Investors Limited Liability Company Agreement, the reporting person is deemed to hold the reported option for the benefit of SV Health Investors, and must exercise the option solely upon the direction of SV Health Investors, which is entitled to the shares issued upon exercise. SV Health Investors may be deemed the indirect beneficial owner of the option, and the reporting person may be deemed the indirect beneficial owner of the option through his indirect interest in SV Health Investors. The reporting person disclaims beneficial ownership of the option except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-035738 · doc4.xml · derivative · entry 3

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,250

Underlying: Common Stock · 31,250 shares

Expires 2027-06-08

F4 · derivative.exercise_date: The stock options will vest 25% on each of September 8, 2020, December 8, 2020, March 8, 2021 and June 8, 2021, provided that if the date of the 2021 annual meeting of stockholders is earlier, the last vesting occurs on the date of the annual meeting. Subject to acceleration of vesting in full upon consummation of a change in control of the Registrant.

SEC source: 0001209191-20-035738 · doc4.xml · nonDerivative · entry 2

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,401

F1 · shares: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock.

F2 · shares: The restricted stock units remain subject to forfeiture until the first anniversary of the date of grant or, if earlier, the date of the next annual meeting of stockholders, as long as the Reporting Person remains in continuous service during the vesting period.

F1 · price: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock.

F3 · balance_after: The Reporting Person has assigned shares issued from prior grants of restricted stock units to SV Health Investors in accordance with its operating agreement and is expected to transfer the shares underlying this reported award upon vesting.

SEC source: 0001209191-20-035738 · doc4.xml · nonDerivative · entry 1

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,901

F1 · shares: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock.

F2 · shares: The restricted stock units remain subject to forfeiture until the first anniversary of the date of grant or, if earlier, the date of the next annual meeting of stockholders, as long as the Reporting Person remains in continuous service during the vesting period.

F1 · price: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock.

F3 · balance_after: The Reporting Person has assigned shares issued from prior grants of restricted stock units to SV Health Investors in accordance with its operating agreement and is expected to transfer the shares underlying this reported award upon vesting.

SEC source: 0001213900-20-013105 · ownership.xml · derivative · entry 1

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By SV Health Investors, LLC

Disclosed balance after: 11,940

Underlying: Common Stock · 11,940 shares

Expires 2030-05-13

F1 · derivative.exercise_date: Award of Stock Options under the Misonix 2017 Equity Incentive Plan. Stock Options vest in on May 13, 2021.

F2 · ownership.nature: The reporting person is a member of SV Health Investors, LLC ("SV Health Investors"). Under SV Health Investors Limited Liability Company Agreement, the reporting person is deemed to hold the reported option for the benefit of SV Health Investors, and must exercise the option solely upon the direction of SV Health Investors, which is entitled to the shares issued upon exercise. SV Health Investors may be deemed the indirect beneficial owner of the option, and the reporting person may be deemed the indirect beneficial owner of the option through his indirect interest in SV Health Investors. The reporting person disclaims beneficial ownership of the option except to the extent of his pecuniary interest therein.

SEC source: 0001213900-19-024776 · ownership.xml · derivative · entry 1

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By SV Health Investors, LLC

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2029-11-22

F1 · derivative.exercise_date: Award of Stock Options under the Misonix 2012 Non-Employee Director Stock Option Plan. Stock Options vest in four equal annual installments on the anniversary of the grant date, November 22, 2019.

F2 · ownership.nature: The reporting person is a member of SV Health Investors, LLC ("SV Health Investors"). Under SV Health Investors Limited Liability Company Agreement, the reporting person is deemed to hold the reported option for the benefit of SV Health Investors, and must exercise the option solely upon the direction of SV Health Investors, which is entitled to the shares issued upon exercise. SV Health Investors may be deemed the indirect beneficial owner of the option, and the reporting person may be deemed the indirect beneficial owner of the option through his indirect interest in SV Health Investors. The reporting person disclaims beneficial ownership of the option except to the extent of his pecuniary interest therein.

SEC source: 0001209191-19-026320 · doc4.xml · derivative · entry 4

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,428

Underlying: Common Stock · 29,428 shares

Expires 2029-04-25

F5 · derivative.exercise_date: The vesting schedule is 25% of the stock option award on July 1, 2019, October 1, 2019, January 1, 2020 and April 1, 2020. No acceleration of vesting for any unvested stock options upon the consummation of a change in control of the registrant.

SEC source: 0001209191-19-026320 · doc4.xml · derivative · entry 3

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,104

Underlying: Common Stock · 29,104 shares

Expires 2029-04-25

F4 · derivative.exercise_date: The vesting schedule is 25% of the stock option award on July 1, 2019, October 1, 2019, January 1, 2020 and April 1, 2020. Subject to acceleration of vesting in full upon consummation of a change in control of the registrant.

SEC source: 0001209191-19-026320 · doc4.xml · nonDerivative · entry 2

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,986

F1 · shares: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock.

F2 · shares: The restricted stock units remain subject to forfeiture until the first anniversary of the date of grant or, if earlier, the date of the next annual meeting of stockholders, as long as the reporting person remains in continuous service during the vesting period.

F1 · price: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock.

F3 · balance_after: Amount of securities beneficially owned following reported transactions reflects the required assignment by the reporting person to an affiliated fund of the right to receive 40,950 shares of common stock upon vesting, on April 24, 2019, of RSUs granted to the reporting person on May 24, 2018.

SEC source: 0001209191-19-026320 · doc4.xml · nonDerivative · entry 1

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,606

F1 · shares: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock.

F2 · shares: The restricted stock units remain subject to forfeiture until the first anniversary of the date of grant or, if earlier, the date of the next annual meeting of stockholders, as long as the reporting person remains in continuous service during the vesting period.

F1 · price: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock.

F3 · balance_after: Amount of securities beneficially owned following reported transactions reflects the required assignment by the reporting person to an affiliated fund of the right to receive 40,950 shares of common stock upon vesting, on April 24, 2019, of RSUs granted to the reporting person on May 24, 2018.

SEC source: 0001209191-18-033657 · doc4.xml · derivative · entry 4

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,580

Underlying: Common Stock · 71,580 shares

Expires 2028-05-24

F2 · security: The Reporting Person elected to receive his annual board of directors' compensation in equity.

F6 · derivative.exercise_date: The vesting schedule is 25% of the stock option award on each of July 1, 2018, October 1, 2018, January 1, 2019 and April 1, 2019.

SEC source: 0001209191-18-033657 · doc4.xml · nonDerivative · entry 1

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,950

F1 · security: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock.

F2 · security: The Reporting Person elected to receive his annual board of directors' compensation in equity.

F1 · price: Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock.

F3 · price: The restricted stock units remain subject to forfeiture until the first anniversary of the date of grant or, if earlier, the date of the next annual meeting of stockholders, as long as the reporting person remains in continuous service during the vesting period.

SEC source: 0001209191-17-035813 · doc4.xml · derivative · entry 1

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2027-05-25

F1 · derivative.exercise_date: Vests 25% per quarter on each quarterly anniversary of the date of grant with the final vesting on the first anniversary of the date of grant.